VEGF/PD-1 bsAb in combination with chemotherapy has shown anti-tumor response in advanced NSCLC and EGFR-TKI-failed NSCLC, with ongoing Phase III trials (NCT05184712) [440]. Here, EGFR is linked to neoplasm.